Impax Laboratories and Dr. Reddy’s have settled their patent infringement dispute over Rytary, a medication used to treat Parkinson’s disease. Walgreens’ three core segments—U.S. pharmacy ...

The recent launch of CREXONT has been particularly noteworthy. Analysts expect CREXONT to achieve at least 50% payer coverage by 2025, which should help offset the impact of Rytary’s loss of ...

Analysts expect CREXONT to achieve at least 50% payer coverage by 2025, which should help offset the impact of Rytary’s loss of exclusivity (LOE) in August 2025. The company is also actively ...

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.

Specialty; Amneal Pharmaceuticals Inc. Jason Daly; Senior Vice President, Chief Legal Officer, Corporate Secretary; Amne ...

As a point of reference, Rytary has 6% market share currently 10 years since its launch. We are very confident in achieving US peak sales of $300 million to $500 million for CREXONT. Our Specialty ...

He added that Amneal expects continued top- and bottom-line growth in 2025, despite the loss of exclusivity for Rytary. Amneal projects 2025 total revenue of $3.0B-$3.1B, driven by double-digit ...

Rune Labs, the leader in precision medicine for Parkinson's Disease (PD), today launched StrivePD Guardian, a personalized care service that combines expert coaching with AI-powered symptom and risk ...

Learn more about whether Amneal Pharmaceuticals, Inc. or HUTCHMED (China) Limited is a better investment based on AAII's A+ ...